“Recurrent Glioblastoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Recurrent Glioblastoma Market.
The Recurrent Glioblastoma Pipeline report embraces in-depth commercial, regulatory, and Recurrent Glioblastoma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Recurrent Glioblastoma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Recurrent Glioblastoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Recurrent Glioblastoma treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Recurrent Glioblastoma therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Recurrent Glioblastoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Recurrent Glioblastoma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Recurrent Glioblastoma therapeutic market.
Recurrent Glioblastoma Therapeutics Landscape
According to the National Institute of Health, Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. The long-term outlook (prognosis) for people with glioblastoma is poor. There is currently no cure and despite treatment, many affected people live less than a year after the initial diagnosis. However, life expectancy following diagnosis depends on many factors.
Glioblastoma treatment is quite challenging, as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. Glioblastoma treatment often comprises a combination of several therapies including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.
There are approx. 50+ key companies developing therapies for Recurrent Glioblastoma. Currently, Ascletis is leading the therapeutics market with its Recurrent Glioblastoma drug candidates in the most advanced stage of clinical development.
Recurrent Glioblastoma Companies Actively Working in the Therapeutic Market Include:
Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, and many others.
Emerging and Marketed Recurrent Glioblastoma Drugs Covered in the Report Include:
-
ASC40: Ascletis
-
GX-I7: Genexine
-
Olinvacimab: PharmAbcine
-
VXM01: VAXIMM AG
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Recurrent Glioblastoma Companies Working in the Market @
https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight
Analysis of Emerging Recurrent Glioblastoma Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NAOral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
Learn How the Recurrent Glioblastoma Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Recurrent Glioblastoma Treatment Patterns
4. Recurrent Glioblastoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Recurrent Glioblastoma Late Stage Products (Phase-III)
7. Recurrent Glioblastoma Mid-Stage Products (Phase-II)
8. Recurrent Glioblastoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Recurrent Glioblastoma Discontinued Products
13. Recurrent Glioblastoma Product Profiles
14. Major Recurrent Glioblastoma Companies in the Market
15. Key Products in the Recurrent Glioblastoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Recurrent Glioblastoma Unmet Needs
18. Recurrent Glioblastoma Future Perspectives
19. Recurrent Glioblastoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Relapsing Multiple Sclerosis (RMS) Market
"Relapsing Multiple Sclerosis (RMS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Relapsing Multiple Sclerosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Relapsing Multiple Sclerosis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research
